Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iotalamic acid is an ionic, high-osmolality iodinated contrast agent used in diagnostic radiology. As a tri-iodinated benzoic acid derivative, it functions by absorbing X-rays, thereby enhancing the visibility of internal structures such as blood vessels, the urinary tract, and joints during radiographic procedures. It is commonly formulated as meglumine or sodium salts (e.g., meglumine iotalamate) for various applications including intravenous urography, angiography, and computed tomography (CT). While newer non-ionic contrast agents have largely superseded high-osmolality agents in many clinical settings due to better tolerability, iotalamic acid remains an established active pharmaceutical ingredient (API) manufactured by companies like Laboratorios Juste for global markets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iotalamic acid.